Dipeptidyl peptidase-4 inhibitors and risk of multiple sclerosis: A Danish nationwide matched case-control study.
BACKGROUND Treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) is a strong risk factor for developing bullous pemphigoid, a dermatological disorder that is itself strongly associated with multiple sclerosis (MS). We therefore hypothesized that DPP-4i would also increase the risk of MS. OBJECTIVE To investigate...